<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bendamustine is an <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> with a <z:chebi fb="0" ids="28925,37598">nitrogen mustard</z:chebi> group and a <z:chebi fb="0" ids="35584">purine</z:chebi>-like <z:chebi fb="0" ids="36622">benzimidazole</z:chebi> group </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to collect <z:hpo ids='HP_0000001'>all</z:hpo> the Italian experiences with this drug in order to evaluate the results in term of response to therapy and toxicities </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients treated in 24 Italian haematological centres with bendamustine alone or in combination with anti-CD20 antibody </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred seventy-five relapsed or refractory <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients were enrolled </plain></SENT>
<SENT sid="4" pm="."><plain>The median age was 69 years (range 26-87) </plain></SENT>
<SENT sid="5" pm="."><plain>Seventy-nine patients were relapsed, 35 were refractory and 61 presented a progressive disease after partial response </plain></SENT>
<SENT sid="6" pm="."><plain>The diagnoses were 60 indolent non-follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 34 diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 48 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 30 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and three peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were evaluable for response: 52 (29%) with complete remission, 72 (43%) with partial response with an overall response rate of 71%, and 51 non-responders </plain></SENT>
<SENT sid="8" pm="."><plain>With a median observation period of 10 months (1-43), 70% of patients are alive </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, this retrospective study shows that treatment with bendamustine alone or in combination with rituximab is a safe and effective regimen in a subset of multi-resistant patients </plain></SENT>
</text></document>